直接抗病毒药物治疗丙型肝炎病毒感染是否增加肝功能失代偿和肾功能下降风险?ERCHIVES研究结果
本研究随访ERCHIVES队列中接受PrOD、索非布韦/西美普韦或索非布韦/雷迪帕韦方案治疗的患者至停药后12周,比较肝功能失代偿、肝移植、死亡及肾功能恶化的发生率。结果显示PrOD组肝功能失代偿发生率与索非布韦/雷迪帕韦组相当,低于索非布韦/西美普韦组,且风险主要见于治疗前已有肝硬化的患者。
要点
- PrOD组肝功能失代偿发生率为10.6/1000人年,索非布韦/西美普韦组为32.4/1000人年,索非布韦/雷迪帕韦组为13.0/1000人年。
- 基线肝硬化患者肝功能失代偿发生率分别为PrOD组36.9、索非布韦/西美普韦组61.8、索非布韦/雷迪帕韦组41.1/1000人年。
- FIB-4评分每增加0.5单位,肝功能失代偿风险在PrOD组HR为1.11,索非布韦/西美普韦组HR为1.03,索非布韦/雷迪帕韦组HR为1.02。
核心结论
- 完成PrOD方案治疗后至12周内,肝功能失代偿发生率与索非布韦/雷迪帕韦方案相当,且低于索非布韦/西美普韦方案。
- 该风险主要见于治疗前已有肝硬化的患者。
研究设计与样本
- ERCHIVES队列研究,随访接受PrOD、索非布韦/西美普韦或索非布韦/雷迪帕韦方案治疗的患者至停药后12周。
- 排除HIV感染、HBsAg阳性以及既存肝功能失代偿诊断和肝细胞癌的患者。
- PrOD组3728人,索非布韦/西美普韦组1578人,索非布韦/雷迪帕韦组10440人。
主要发现
- 肝功能失代偿发生率(每1000人年,95%CI):PrOD组10.6(5.89-17.36),索非布韦/西美普韦组32.4(20.74-48.16),索非布韦/雷迪帕韦组13.0(9.74-17.10)。
- 基线肝硬化患者肝功能失代偿发生率(每1000人年,95%CI):PrOD组36.9(19.1-64.5),索非布韦/西美普韦组61.8(38.2-94.5),索非布韦/雷迪帕韦组41.1(29.9-55.2)。
- 基线无肝硬化患者肝功能失代偿发生率(每1000人年,95%CI):PrOD组2.7(0.6-8.0),索非布韦/西美普韦组7.5(1.5-21.8),索非布韦/雷迪帕韦组2.7(1.2-5.4)。
- FIB-4评分每增加0.5单位与肝功能失代偿风险增加相关:PrOD组HR 1.11(95%CI 1.07-1.16),索非布韦/西美普韦组HR 1.03(95%CI 1.01-1.05),索非布韦/雷迪帕韦组HR 1.02(95%CI 1.01-1.03)。
- 无死亡病例;eGFR下降>30 ml/min/1.73 m2的比例在PrOD组较高,但肝硬化存在与否似乎不影响该比例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Directly acting antiviral agents (DAA) have been associated with hepatic decompensation, especially in patients with pre-treatment cirrhosis, but this risk is not well defined. AIM: To determine the incidence of hepatic decompensation, liver transplantation, death and worsening renal function in patients treated with a Paritaprevir/ritonavir, Ombitasvir, Dasabuvir (PrOD), sofosbuvir/simeprevir or sofosbuvir/ledipasvir regimen. METHODS: We followed ERCHIVES participants treated with the above regimens for up to 12 weeks post-treatment. We excluded those with HIV, HBsAg+ and pre-existing diagnosis of hepatic decompensation and hepatocellular carcinoma. RESULTS: Of 3728 persons on PrOD, 1578 on sofosbuvir/simeprevir and 10 440 on sofosbuvir/ledipasvir, incidence rates (95% CI) of hepatic decompensation/1000 patient-years were 10.6 (5.89-17.36) for the PrOD, 32.4 (20.74-48.16) for the sofosbuvir/simeprevir and 13.0 (9.74-17.10) for the sofosbuvir/ledipasvir. Among those with baseline cirrhosis, these rates were 36.9 (19.1-64.5), 61.8 (38.2-94.5) and 41.1 (29.9-55.2) respectively, while among those without cirrhosis at baseline, these rates were 2.7 (0.6-8.0), 7.5 (1.5-21.8) and 2.7 (1.2-5.4). Advanced fibrosis was associated with increased risk of hepatic decompensation in all groups [HR (95% CI) per 0.5 unit increase in FIB-4 score: PrOD 1.11 (1.07-1.16); sofosbuvir/simeprevir 1.03 (1.01-1.05); sofosbuvir/ledipasvir 1.02 (1.01-1.03)]. There were no deaths. Proportion of persons with eGFR decrease >30 ml/min/1.73 m2 was higher among the PrOD group, but presence of cirrhosis did not appear to affect this. CONCLUSIONS: The incidence of hepatic decompensation in persons treated with PrOD, up to 12 weeks after completion of treatment, was comparable to those treated with sofosbuvir/ledipasvir regimen, and was lower than among those treated with a sofosbuvir/simeprevir regimen. Such risk was predominantly observed in those with pre-treatment cirrhosis.
引用
- Butt AA, Ren Y, Marks K, et al. Do directly acting antiviral agents for HCV increase the risk of hepatic decompensation and decline in renal function? Results from ERCHIVES. Aliment Pharmacol Ther. 2016. PMID: 27813162. doi:10.1111/apt.13837
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。